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ABSTRACT As a direct correlation between aging
and the risk of onset of vascular disease has been
universally accepted, we prepared an in vitro aging
model consisting in sequential passages of human
aortic smooth muscle cells (AoSMC) in order to evalu-
ate the cell behavior changes during aging. Because
matrix metalloproteinases (MMP) are actively involved
in matrix remodeling and disease outcome, in our
model we found active MMP-2 only in the conditioned
medium of young AoSMCs, whereas aged cells showed
only the inactive zymogen form of MMP-2 (pro-MMP-
2). We ascribed the pro-MMP-2 activation in young cells
to an increase in membrane type 1 matrix metallopro-
teinase (MT1-MMP) content. Furthermore, we found
that transcripts coding for tissue inhibitor of metallo-
proteinases (TIMPs) were up-regulated in aged cells,
and this increase of TIMPs could also prevent pro-
MMP-2 activation in aged cells. Moreover, we demon-
strated that young AoSMCs possess higher migratory
capabilities than aged cells. The young AoSMC migra-
tion can be inhibited by adding TIMP-1 and TIMP-2 to
the cells reproducing aged AoSMC migratory behavior.
Finally, the role of MMP-2 and TIMP-2 in AoSMC
migration was confirmed silencing MMP-2 and TIMP-2
in young and aged AoSMCs, respectively; therefore, in
this study we showed that these enzymes play a pivotal
role in the regulation of the AoSMCmigration during in
vitro aging.—Vigetti, D., Moretto, P., Viola, M., Gena-
setti, A., Rizzi, M., Karousou, E., Pallotti, F., De Luca,
G., Passi, A. Matrix metalloproteinase 2 and tissue
inhibitors of metalloproteinases regulate human aortic
smooth muscle cell migration during in vitro aging.
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Smooth muscle cells (SMCs) are mainly located
within the tunica media of blood vessels in a contractile
state, expressing specific genes essentials for SMC func-
tions, such as regulation of vessel tone and blood
pressure (1). Under pathological conditions, such as
vessel injury or atherosclerotic plaque development,
SMCs become exposed to certain growth factors, in-
flammatory cytokines, and other circulating compo-
nents that induce a transformation from the contractile
to a synthetic state (2). In the latter state only do SMCs
acquire the ability to proliferate, migrate, and accumu-
late within the intimal layer of arteries under the
influence of chemotaxis-inducing growth factors. Dur-
ing migration, SMCs have been shown to digest major
extracellular barriers such as basal membranes, inter-
stitial collagens, and proteoglycans (3–5). This enzy-
matic breakdown of ECM components is mediated by
the tightly regulated activity of proteases (6, 7). Within
this group of proteases, the family of matrix metallo-
proteinases (MMPs) is essential for the digestion of
ECM components such as collagens, gelatins, or pro-
teoglycans (5, 9). In this process, MMPs can release
growth factors bound to specific proteoglycans (i.e.,
heparan sulfate proteoglycan can bind FGF-2 activity)
(9), thus regulating the viability of factors involved in
SMC migration and in the pathological response of
surrounding cells (10).
The two gelatinases MMP-2 and MMP-9 have received
particular attention in the analysis of vascular remod-
eling and, at least in vitro, both enzymes have very
similar substrate specificity. MMP-2 has been demon-
strated to degrade native type IV, V, VII, and X colla-
gen, as well as denaturated collagens, proteoglycans,
elastin, and growth factors (8). Expression of the two
gelatinases in the vascular wall is strictly controlled;
MMP-2 shows a basal expression in the media, whereas
MMP-9 expression is detectable after injury or inflam-
matory stimulation (11). However, MMP-2 has been
shown to possess an altered synthesis and activation
during vessel injury and cytokine treatment (12).
The synthesis and activation of MMPs constitute a
well-controlled process in which zymogen, the inactive
form of the MMPs, is cleaved to produce the active
form. In this process, membrane type 1 metalloprotein-
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ase (MT1-MMP) complex plays a pivotal role in the
specific activation of pro-MMP-2 (13). On the other
hand, tissue inhibitors of metalloproteinases (TIMPs)
can interact with active MMPs to inhibit their action. In
fact, it has been demonstrated that TIMP-1 and TIMP-2
are the main proteins involved in such processes (14,
15). Moreover, some investigators have suggested a role
for TIMPs in preventing morphological modifications
of the vascular structures during degenerative diseases
(16–18).
It is known that the risk for atherosclerosis or other
vascular diseases correlates with mutated proliferative
and migratory properties of SMCs during aging (19–
21). Moreover, biochemical analyses of normal vs.
altered vessels show several modifications of ECM com-
ponents (22) that clearly involved alterations of the
enzymes responsible for ECM synthesis and/or degra-
dation. In fact, in thick intima of aged rats MMP-2 is
increased (23), and mice with genetic deletions of
MMP-2 show a decreased intima thickness compared to
wild-type animals (6), indicating the important role of
this enzyme in such phenomenon.
Previous observations reported that an altered ex-
pression of enzymes regulating the ECM turnover are
implicated in vascular diseases (22); here we describe
that a fine regulation of MMP-2 and TIMPs can modu-
late the migration of human aortic SMCs (AoSMCs)
during in vitro aging.
MATERIALS AND METHODS
Cell culture
Human primary aortic smooth muscle cells (AoSMCs, donor
age 17, male) were purchased from Cambrex and grown in
SmGm2 complete culture medium (Cambrex, Baltimore,
MD, USA) supplemented with 5% FBS. This cell culture
medium was used in all the experiments. The cultures were
maintained in an atmosphere of humidified 95% air/5% CO2
at 37°C. Whenever the culture became nearly confluent, the
cells were trypsinized, counted using trypan blue exclusion,
and subcultured at a density of 3500 cells/cm2. Population
doublings (PD) were determined at each passage and calcu-
lated as follows: PD  log (number of cells obtained/initial
number of cells)/log 2. In the experiments 4 PD and 18 PD
cells were used and referred as young and aged AoSMCs,
respectively. The senescent phenotype was confirmed by
-galactosidase activity assay (Calbiochem, San Diego, CA,
USA) as described (24) and p16INK4a (hereafter p16) mRNA
expression (25).
Immunofluorescence
Young and aged AoSMCs grown on coverslips were rinsed
with PBS and fixed in methanol. The coverslips were prein-
cubated with PBS containing 2% FBS and incubated with a
solution containing anti- smooth muscle actin (-SMA)
monoclonal antibodies (Clone 1A4, Sigma; 1:1000) in PBS
containing 2% FBS for overnight at 4°C. The coverslips were
washed with PBS, then incubated with a solution containing
fluorescein conjugated anti-mouse immunoglobulin (HL)
(1:500) in PBS containing 2% FBS. Polymerized actin fila-
ments were detected on incubating paraformaldehyde fixed
cells with rhodamine-conjugated phalloidin (Molecular
Probes, Eugene, OR, USA; dilution 1:40). Fluorescence im-
ages were obtained using Delta Vision deconvolution system.
Quantitative RT-PCR
Total RNA from both young and aged AoSMCs was extracted
using Trizol reagent (Invitrogen, San Diego, CA, USA) fol-
lowing the manufacturer’s protocol. Total RNA from normal
fetal aorta (Stratagene, San Diego, CA, USA) and total RNA
from adult aorta (Ambion, Austin, TX, USA) were used to
detect the gene of interest in in vivo conditions. To remove
DNA contamination, DNase (Ambion) treatment was per-
formed in all samples. One g of total RNA was retrotrans-
cribed using high capacity cDNA synthesis kit (Applied Bio-
systems, Foster City, CA, USA) for 2 h at 37°C.
Quantitative real-time RT-PCR was performed on Abi
Prism 7000 instrument (Applied Biosystems) using Taqman
Universal PCR Master Mix (Applied Biosystems) following
manufacturer’s instructions. Probe and primers were from
developed TaqMan gene expression assay reagents (Applied
Biosystems). The following TaqMan gene expression assays
were used: MMP-2 (Hs00234422), MMP-9 (Hs00234579),
TIMP-1 (Hs00171558), TIMP-2 (Hs00234278), -SMA
(Hs00426835), calponin (Hs00154543), p16 (CDKN2A;
Hs00233365), MT1-MMP (also known as MMP14,
Hs00237119), and RNAseP (Hs00706565). Fluorescent sig-
nals generated during PCR amplifications were monitored
and analyzed with Abi Prism 7000 SDS software (Applied
Biosystems). Comparison of the amount of each gene tran-
script among different samples was made using RNAseP as
reference. Standard curves were generated by serial dilution
of cDNA and the relative quantitative evaluation of target
gene levels was performed by comparing Cts (Applied
Biosystems user bulletin number 2).
Zymography
To detect MMP-2 and MMP-9 activities, conditioned medium
from young and aged AoSMCs was electrophoresed on SDS-
polyacrylamide gels containing 1 mg/ml gelatin. Samples
were loaded in the gels without denaturization in the pres-
ence of reducing agents. Gel was washed at room temperature
for 2 h in 2.5% Triton X-100 and incubated overnight at 37°C
in 10 mM CaCl2, 150 mM NaCl, and 50 mM Tris-HCl, pH 7.5
buffer. The gel was stained in 2% (v/v) Coomassie blue G-250
and photographed on a light box after appropriate destain-
ing. Proteolysis was detected as a white zone in a dark blue
field.
Quantification of MMP-2
The quantification of MMP2 was done by using the ELISA kit
Matrix Metalloproteinase-2 Biotrack Activity Assay System
(Amersham Biosciences, Little Chalfont, UK) following the
manufacturer’s instruction. To determine total MMP-2 activ-
ity (i.e., pro- plus active MMP-2), samples were treated with
p-aminophenylmercuric acetate (APMA), then tested with the
ELISA kit reported above. Plates were read in a Biotrack
ELISA reader (Amersham) at 405 nM.
Reverse zymography
For detection of TIMP-1 and TIMP-2 activities, reverse zymog-
raphy procedures were carried out as described by Oliver et
al. (26). Briefly, young and aged AoSMC conditioned me-
dium was concentrated 10-fold using Amicon filter systems
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(3000 Da cutoff) and loaded onto a 15% polyacrylamide gel
containing 15 mg/ml gelatin and 50 ng/ml active recombi-
nant human MMP-2 (Calbiochem) without denaturing and
reducing agents. Normalization of sample loading on each
gel was obtained by application of an equal volume of cell
conditioned media standardized to total cell number. After
electrophoresis, gels were rinsed in 2.5% Triton X-100 to
remove SDS and incubated overnight at 37°C in 10 mM
CaCl2, 150 mM NaCl, and 50 mM Tris-HCl, pH 7.5 buffer.
Subsequently gels were stained with Coomassie blue G-250
and destained with 30% methanol 10% glacial acetic acid
solution. The presence of TIMPs in the samples inhibits
MMP-2 activity visualizing dark bands on a clear background.
The reverse zymography procedure was also used to esti-
mate the TIMPs activity in cell membrane protein extracts
that was prepared scraping AoSMCs into cells were washed
with PBS and scraped into ice-cold lysis buffer (20 mM
Tris-HCl, pH 7.4, 150 mM NaCl) containing protease inhibi-
tory cocktail (Roche, Nutley, NJ, USA) and lysed by sonica-
tion. The extract was centrifuged at 15,000 g for 10 min at 4°C
and the pellet was re-extracted in lysis buffer supplemented
with 0.5% Triton X-100 on ice, yielding the membrane
fraction. Protein concentrations were determined using the
Bradford method (Bio-Rad, Hercules, CA, USA) as described
by the supplier, with BSA as a standard.
Migration assay
Cell migration assay was performed using Transwell (Costar,
Cambridge, MA, USA) system, which allows cells to migrate
throughout a 8 m pore size polycarbonate gelatin-coated
membrane. Briefly, Transwell gelatin coating was performed
in 0.5% gelatin for 2 h at 37°C and drying overnight at room
temperature. Cells were trypsinized, washed, and resus-
pended in serum-free SmGm2. 1  105 cells were added to
the upper chamber of Transwells. The lower chamber was
filled with 1.5 ml serum-free SmGm2 or 1.5 ml serum-free
SmGm2 containing 0.3 g/ml TIMP-1 (Calbiochem), or 0.3
g/ml TIMP-2 (Calbiochem) or 5 g/ml GM6001 (a chem-
ical inhibitor of MMPs purchased from Chemicon, El Seg-
undo, CA, USA), or 0.3 g/ml active-MMP-2 (Calbiochem).
After 6 h, filters were removed and cells remaining on the
upper surface of the membrane were removed with a cell
scraper. Membranes were then washed with PBS, and cells
present beneath the membrane were fixed with cold metha-
nol for 15 min and stained with 0.2% Crystal violet. Cell count
was performed under a light microscope (magnification 20)
considering 6 high-power unrelated fields (HPF). Triplicate
independent experiments were performed.
Western blot
Young and aged AoSMC conditioned medium was concen-
trated 10-fold using Amicon filter systems (3000 Da cutoff).
To detect MMP-2, the concentrated medium was further
purified using gelatin-Sepharose (Amersham Pharmacia Bio-
tech) (27). Normalization of protein loading on each blot was
obtained by application of an equal volume of cell condi-
tioned media standardized to total cell number. After SDS-
PAGE under reducing conditions, proteins were blotted onto
PVDF membrane (Amersham Bioscience). After transfer, the
blots were stained with Ponceau S (Sigma Chemical Co., St.
Louis, MO, USA) to confirm equal loading. Membranes were
probed with polyclonal anti-MMP-2 antibodies (IM33T, Cal-
biochem) or anti-TIMP-2 monoclonal antibody (mAb)
(IM82T, Calbiochem). Signals were revealed using secondary
peroxidase-conjugated antibodies and the band visualization
was carried out by the chemiluminescence method described
by Amersham Pharmacia Biotech.
To detect MT1-MMP, cell extracts were prepared from
young and aged AoSMCs by means of radio-immuno-precip-
itation assay buffer (50 Mm Tris-HCl pH 7.4, 150 mM NaCl,
1% (v/v) Igepal CA-630 (Sigma, I-3021) supplemented with
protease inhibitor cocktail (Roche)) and anti-MT1-MMP mAb
(Calbiochem) was used as described above. As a control for
protein loading and for normalization, -tubulin was also
revealed on MT1-MMP blots using a mAb purchased from
Sigma.
MMP-2 and TIMP-2 silencing
Small interfering RNA (siRNA) was adopted to reduce MMP-2
and TIMP-2 expression in young and aged AoSMCs, respec-
tively. MMP-2 validated siRNA kit (code 51191), TIMP-2
predesigned siRNA (code 118689) and negative control
siRNA #1 kit (scramble, code 4611) were purchased from
Ambion and used as recommended. Transfections were per-
formed using Nucleofector apparatus (Amaxa, Gaithersburg,
MD, USA) and Human AoSMC (aortic smooth muscle cells)
Nucleofector™ Kit with 5 g of either MMP-2 siRNA, TIMP-2
siRNA, or scramble siRNA. Two micrgrams of Green fluores-
cent protein (GFP) plasmid (Amaxa) was used to test the
transfection efficiency. After 48 h of incubation, half of the
transfected cells were used for migration experiments. Total
RNA was extracted from the remaining cells and the reduced
MMP-2 expression was checked by real-time PCR. Condi-
tioned cell medium was used in gel zymography experiments
to evaluate the remaining MMP-2 activity after siRNA trans-
fections.
Statistical analyses
Unpaired Student’s t test was performed for statistical analy-
ses using Origin 7.5 software (Microcal Software, Studio City,
CA, USA). Experiments were performed in triplicate and data
are expressed as the mean  se.
RESULTS
Identification of gelatinase activities in young and
aged AoSMCs
We set up an in vitro aging model in which commercial
AoSMCs (Cambrex) have been cultured in complete-
SmGm2 medium (Cambrex) for several population
doublings (PD). We consider as “young” the cells with
4 PD after thawing, and as “aged” the cells with 18 PD
after thawing. The cytochemical senescent phenotype
was examined by using senescence-associated -galacto-
sidase (SA -Gal) activity, which has been shown to be
a marker of senescence in vascular cells as well as in
fibroblasts (28). As shown in Fig. 1A, B, almost all aged
AoSMCs revealed SA -Gal activity, while only a few
young cells were stained in cultures at lower PD.
Moreover, the enlarged size of 18 PD AoSMCs is typical
of aged (near to senescence) cells (28).
We have evaluated p16INK4a (hereafter p16) another
cell senescence marker (29) unrelated to SA -Gal
activity. We quantified the p16 mRNA, which was
recently described to increase its stability during repli-
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cative senescence (25). We have performed quantita-
tive real-time RT-PCR using the TaqMan gene expres-
sion assay developed by Applied Biosystems and, as
shown in Fig. 1C, a clear and statistically significant
accumulation of p16 transcript was detected in aged
AoSMCs, confirming that 18 PD AoSMCs can be con-
sidered “aged” expressing the typical marker of senes-
cent cells.
To verify that the numerous culture passages did not
affect the AoSMC phenotype, we have considered
-SMA and calponin, well-known markers of SMC. By
means of quantitative real-time RT-PCR, we detected
that all the above cited markers were expressed at the
same levels both in young and aged AoSMCs (results
not shown). Moreover, immunolocalizations and West-
ern blot analyses were performed to quantify and
visualize the SMA (Fig. 2A, B, G), and no substantial
differences between young and aged AoSMCs were
detected. To further confirm this result, we visualized
polymerized actin by means of phalloidin conjugated
with rhodamine (30). As shown in Fig. 2C–F, the typical
SMC actin filaments were detected in both young and
aged AoSMCs. Moreover, the same cellular distribution
of such filaments revealed that no dedifferentiation
events occurred during subsequent cell passages.
To analyze the gelatinase activities secreted into the
cell medium of young and aged AoSMCs, we have
harvested the conditioned culture medium and loaded
onto a zymography gel. As shown in Fig. 3A, both young
and aged cells produced a 72 kDa band of gelatinase
activity corresponding to the purified zymogen of ma-
trix metalloproteinase 2 from Sigma (pro-MMP-2).
Surprisingly, the 	66 kDa band corresponding to the
fully activated MMP-2 is detectable only in the condi-
tioned cell culture medium of young AoSMCs. No
other gelatinase activity bands were observed on the
gel, suggesting that the other well-known MMP-9 is not
present in a detectable amount.
To quantify gelatinase activity, we performed MMP-2
ELISA tests and found that the total gelatinase activity
(i.e., pro- plus active MMP-2) was 18.7 ng/ml and 18.1
ng/ml in conditioned culture medium of young and
aged AoSMCs, respectively. Accordingly with the zy-
Figure 1. AoSMCs during in vitro aging express senescence
markers. A, B) Detection of SA--gal activity in young (A) or
aged (B) AoSMCs using phase contrast microscope (Olym-
pus) at the same magnification with a 20 objective. C)
Quantitative real-time RT-PCR quantification of p16 cDNA in
young and aged AoSMCs. *P 
 0.01 aged vs. young. Relative
expression is expressed in arbitrary units.
Figure 2. AoSMCs during in vitro aging maintain smooth
muscle phenotype. A, B) Immunolocalization of -SMA
(green) in young (A) and aged (B) AoSMCs. Nuclei are
stained with DAPI (blue). The same magnification (40
objective) were used for both the photomicrographs. C–F)
Localization of actin filaments by rhodamine conjugated
phalloidin (red) in young (C–E) and aged (D–F) AoSMCs.
Nuclei are stained with DAPI (blue). The same magnification
(40 objective) was used for panels C, D in both photomi-
crographs. Deconvolved images acquired by Delta Vision
system are shown in panels E, F (with 100 objective) for
young and aged AoSMCs, respectively. G) A Western blot
experiment showing -SMA in cell extract of young and aged
AoSMCs. To standardize protein loading,  tubulin was also
detected.
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mography experiment, active MMP-2 (i.e., without
chemical activation of pro-MMP-2 in MMP-2 with APMA)
in the conditioned culture medium of young AoSMC was
7.5 ng/ml in young, whereas in aged AoSMC culture,
medium was below the detection limit of the kit (i.e., 0.2
ng/ml).
To identify the gelatinase bands, we have performed
Western blot analyses using concentrated conditioned
cell culture medium of young and aged AoSMCs with
anti-MMP-2 antibodies. As MMP-2 was expressed at low
concentration to be visualized without concentration,
before the SDS-PAGE separation we performed an-
other affinity purification step using gelatin-Sepharose
as outlined by Mazzieri et al. (27). As shown in Fig. 3B,
a 72 kDa band corresponding to pro-MMP-2 is present
in similar amounts both in young and aged AoSMC
conditioned medium. On the other hand, the 66 kDa
band, corresponding to the active form of MMP-2, is
visualized only in young conditioned medium as ex-
pected from zymography.
Quantification of the pro-MMP-2 activator
As one of the major activator of pro-MMP-2 in physio-
logical conditions is membrane type 1 MMP (MT1-
MMP) (13), we have quantified its synthesis in young
and aged AoSMCs. By quantitative real-time RT-PCR,
we have found that the concentration of mRNA coding
for MT1-MMP was reduced by 	60% in aged vs. young
AoSMCs (Fig. 4A). We also detected MT1-MMP at
protein concentrations by Western blot. MT1-MMP is
synthesized as a 65 kDa proenzyme, which is activated
by proteolytic cleavage producing the 54 kDa enzyme.
Another proteolytic cleavage converts the active en-
zyme into a 45 kDa inactive protein (13). Using a
monoclonal anti-MT1-MMP antibody, we showed that
the active MT1-MMP was present in both young and
aged AoSMC extracts, even if this band was more
intense in young than aged cells (Fig. 4B).
As MT1-MMP activates pro-MMP-2 through the for-
mation of a complex with TIMP2, we quantified the
cellular TIMP2 performing reverse zymography exper-
iments on total protein extracts. As shown in Fig. 4C,
TIMP2 was present at a higher concentration in young
than in aged AoSMCs.
Quantification of MMPs and TIMPs during
AoSMC aging
To better define MMPs expression during in vitro aging
of AoSMCs, we quantified the transcripts coding for
MMPs by quantitative real-time RT-PCR. Figure 5A
shows the relative expression of MMP-2 and MMP-9
mRNA normalized for the content of RNAseP (house-
keeping gene). Because the activities of MMP-2 and
MMP-9 are strongly regulated by tissue inhibitor of
metalloproteinases (TIMP), we also quantified the tran-
scripts coding for such proteins (named TIMP-1 and
TIMP-2). As reported in Fig. 5A, the quantity of MMP-2
mRNA is not significantly different from young to aged
AoSMCs, whereas, as expected from the zymography
experiment, no MMP-9 transcripts were detectable.
The concentration of TIMP-1 and TIMP-2 mRNAs
varied during aging, and their amounts show a signifi-
cant increase in aged AoSMCs (P
0.001).
To visualize TIMP activities present in the condi-
tioned cell culture medium of AoSMCs, we performed
reverse zymography analyses. Young and aged AoSMC
conditioned medium contained inhibitory bands cor-
responding to TIMP activities. The 31 and 21 kDa
bands corresponded to TIMP-1 and TIMP-2 proteins,
respectively (results not shown). Besides these two
gelatinase inhibitory activities, two bands at 	23 kDa
are present in the conditioned cell culture medium and
could be attributed to the glycosylated and unglycosy-
lated forms of TIMP3, which is not directly correlated
in MMP-2 activity regulation (8).
Western blot analyses were carried out to better
Figure 3. Gelatinase activities during in vitro aging of
AoSMCs. A) Zymography analysis. Fifteen microliters of con-
ditioned medium (CM) deriving from 106 of either young or
aged AoSMCs were loaded onto gelatin-polyacrylamide gel as
stated in Materials and Methods. Standard lane contains both
active and latent form of MMP-2 (Sigma) and was used as
reference. The data shown are representative of two separate
experiments. B) Western blot analysis of MMP-2. Concen-
trated and gelatin-Sepharose purified conditioned medium
from young and aged AoSMCs (deriving from the same
amount of cells) were electrophoresed and blotted on PVDF
membranes and incubated with anti-MMP-2 antibodies.
MMP-2 lane is loaded with both latent and active MMP-2
(Sigma).
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visualize the presence of TIMP-2 in young and aged
AoSMC conditioned medium. As shown in Fig. 5B, a
band of 21.0 kDa corresponding to TIMP-2 is visible in
both conditioned media in amounts related to the
mRNA expression pattern. The recombinant human
TIMP-2 (rh-TIMP-2, Calbiochem) used as control in the
Western blot and reverse zymography experiments
migrated as a 24.0 kDa protein in reducing gels (Fig.
5B) and as a 21 kDa protein in nonreducing gels (result
not shown), as expected from the rh-TIMP-2 character-
ization performed by the manufacturer.
To determine whether our in vitro cell aging system
could be representative of the gene expression present
in in vivo conditions, we performed quantitative real-
time RT-PCR on normal aorta RNA prepared from
healthy donors of different ages. As a young sample, we
used a pool of 5 different fetal aorta RNAs purchased
from Invitrogen; as an adult sample we used a pool of
5 different aorta RNAs from donors of 65 years old
(Ambion). The results reported in Fig. 6 clearly indi-
cate that MT1-MMP, TIMP1 and TIMP2 mRNA levels
correlate well with that obtained from AoSMC gene
Figure 4. MT1-MMP expression in young and aged AoSMCs.
A) Quantification of the transcript coding for MT1-MMP by
real-time RT-PCR in young and aged AoSMCs. Relative ex-
pression in arbitrary units. *P 
 0.01 young vs. aged. B)
Western blot analysis of MT1-MMP. 20 g of cell lysates from
young and aged AoSMCs were electrophoresed and blotted
on PVDF membranes, and incubated with anti-MT1-MMP
antibodies. As loading control,  tubulin has been detected.
C) Reverse zymography experiment performed on 10 g of
membrane extracted proteins from young and aged AoSMCs
showing TIMP2 activity associated to cell extracts. Recombi-
nant human TIMP2 (rhTIMP2) was loaded as a reference.
Figure 5. Quantitative analysis of MMPs and TIMPs during
AoSMC aging. A) Quantification of the transcripts coding for
MMP-2, MMP-9, TIMP-1, and TIMP-2 by real-time RT-PCR in
young and aged AoSMCs. Relative expression is expressed in
arbitrary units. No statistical difference is observable in the
quantity of MMP-2 mRNA in young or aged AoSMCs. Tran-
scripts coding for MMP-9 were not detectable (n.d.). B)
Reverse zymography analysis indicating the presence of TIMP
activities in concentrated young and aged AoSMCs condi-
tioned media (CM). Recombinant human TIMP-1 (rh-
TIMP1) and recombinant human TIMP-2 (rh-TIMP2) were
used as standard. C) Quantification of TIMP2 by Western blot
analysis in 10 concentrated young and aged AoSMC condi-
tioned medium using anti-TIMP-2 antibodies. One represen-
tative reverse zymogram and Western blot experiments are
shown.
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expression experiments (Fig. 5A) whereas MMP2 tran-
script seems to be expressed at higher levels in aged
aorta.
MMP-2 and TIMPs modulate AoSMC migration
during aging
Metalloprotease activity is strongly implicated in cell
migration, control of ECM degradation, and the release
of proteoglycan bound growth factors. Therefore, we
have supposed that young AoSMCs could exhibit a
migratory behavior since these cells possess active
MMP-2 and low TIMP expression. To test this hypoth-
esis, we performed a migration assay using gelatin-
coated Transwell apparatus (Costar). Figure 7A shows
one HPF photograph that clearly demonstrates that
young AoSMCs migrate at a higher rate than aged
AoSMCs. The same result is shown in Fig. 7B, C
comparing the young and aged control bars of the
graph.
We have added to the lower chamber of the Trans-
well apparatus human purified TIMP-1 and TIMP-2
(Calbiochem) to test the possibility that TIMP-1 and
TIMP-2 expression could modify the migration of
AoSMCs (Fig. 7B, C). The addition of these inhibitory
proteins reduced significantly the migration of young
AoSMCs (P
0.05 and P
0.001 for TIMP-1 and TIMP-2,
respectively). Moreover, the addition of GM6001, a
chemical inhibitor of MMPs, greatly reduced the migra-
tion of both young and aged AoSMCs. On the other
hand, the addition of human purified MMP-2 (Calbio-
chem) stimulated the migration of young AoSMCs and,
to a lesser extent, that of aged AoSMCs.
We have also silenced the MMP-2 expression in
young AoSMCs by using siRNA, thus verifying the
specificity of MMP-2 related migratory behavior. The
use of Nucleofector apparatus (Amaxa) and the human
primary AoSMC Nucleofector kit (Amaxa) gave a 60%
transfection efficiency. The reduced expression of
MMP-2 was checked 48 h after siRNA transfection by
both real-time RT-PCR and zymography. As shown in
Fig. 8A, the levels of mRNA coding for MMP-2 were
greatly reduced in siRNA transfected young AoSMCs,
reaching 	95% of inhibition. Scrambled siRNA trans-
fected cells confirm the specificity of the silencing
Figure 6. Quantitative analysis of transcripts coding for MT1-
MMP, MMPs, and TIMPs in in vivo conditions. Quantification
of the transcripts coding for MT1-MMP, MMP-2, MMP-9,
TIMP-1, and TIMP-2 by real-time RT-PCR in cDNA derived
from fetal and aged aorta. Relative expression is expressed in
arbitrary units. *P
 0.01 young vs. aged; **P
 0.05 young vs.
aged.
Figure 7. Migration of young and aged AoSMCs
on gelatin-coated Transwell apparatus. A) Photo-
graph of migrated young or aged AoSMCs after
6 h of incubation without adding any modulators
in the lower chamber of the Transwell. One
representative high-power microscope fields
(HPF) is shown (magnification 20). The mean
number  se of cell migrated per HPF and the
significance between young and aged cells is
reported. 1  105 young AoSMCs (B) or the same
amount of aged AoSMCs (C) were seeded on the
upper side of the chamber while modulators (i.e.,
TIMP-1, TIMP-2, GM6001, or active MMP-2) have
been added to the lower compartment at the
concentration indicated in Materials and Meth-
ods. After 6 h of incubation at 37°C, migrated
cells were stained with Crystal violet and counted.
The number of migrated cells per HPF is re-
ported.
1124 Vol. 20 June 2006 VIGETTI ET AL.The FASEB Journal
effect. Accordingly, the reduced expression of MMP-2
mRNA, in zymography MMP-2 activity is strongly re-
duced in conditioned medium of young AoSMC trans-
fected with siRNA against MMP-2 compared with the
gelatinase activity of either control untransfected or
scramble siRNA transfected cells (Fig. 8B). To better
quantify the MMP-2 activity, ELISA tests revealed that
the total gelatinase concentration was 4.8, 18.0, and
17.9 ng/ml in MMP-2 siRNA, scramble siRNA, and
control transfected young AoSMCs, respectively. Active
MMP-2 was 2.4, 8.8, and 7.8 ng/ml in MMP-2 siRNA,
scramble siRNA, and control transfected young
AoSMCs, respectively, corresponding to an active
MMP-2 inhibition of 	70%.
MMP-2-silenced young AoSMCs showed a significant
decrease in migratory behavior (P
0.01) as clearly
shown in Fig. 8C. This reduced migration capability was
actually due to MMP-2 as the scramble siRNA trans-
fected cells migrated as untransfected young AoSMCs
(Fig. 8C). Moreover, we can exclude that the lower
extent of migration of MMP-2 siRNA transfected cells
could be due to a specific toxic effect of MMP-2 siRNA,
since purified active MMP-2 added to these cells re-
stored the normal migratory behavior almost to the
concentration of the control (i.e., siRNA scramble)
(Fig. 8C).
To demonstrate the pivotal role of MMP-2:TIMP-2
ratio in the control of migration during aging, we
silenced the TIMP-2 expression in aged AoSMC by
siRNA. Using the same conditions of young AoSMC, we
obtained a transfection efficiency of 	55% (result not
shown). The reduced expression of TIMP-2 was
checked 48 h after siRNA transfection by real-time
RT-PCR and Western blot. As shown in Fig. 9A, the
levels of mRNA coding for TIMP-2 were greatly reduced
in TIMP-2 siRNA transfected aged AoSMCs reaching
	80% of inhibition, whereas scrambled siRNA trans-
fected cells showed a TIMP-2 expression concentration
similar to untransfected cells. The reduced expression
of TIMP-2 was also confirmed detecting 21 kDa TIMP-2
protein in the conditioned culture medium of siRNA
transfected cells by means of Western blot (Fig. 9B). We
have determined an activation of MMP-2 in the condi-
tioned medium of aged AoSMCs transfected with
siRNA against TIMP-2 (result not shown).
TIMP-2-silenced aged AoSMCs showed a significant
increase in migratory behavior (P
0.01) as clearly
shown in Fig. 9C. The specificity of this latter result was
supported by evidence that the migration of scramble
siRNA transfected and untransfected cells were compa-
rable (Fig. 9C). Moreover, the addition of human
purified TIMP-2 to aged TIMP-2 silenced cells, which
determined a reduction of migration to the control
levels (Fig 9B), confirmed that the fine balancing of
MMP-2 and TIMP-2 was critical in controlling the
migration during in vitro aging of AoSMC.
DISCUSSION
Aging is a complex and multifactorial process that
involves changes in every part of the organism. Such
adaptations correspond to dramatic modifications at
Figure 8. Knockdown of MMP-2 in young AoSMCs. A) Quanti-
fication of the transcripts coding for MMP-2 by real-time RT-
PCR in young cells transfected with 5 g of siRNA against
MMP-2 (siMMP-2) or 5 g of scramble siRNA (scramble) after
48 h. The control experiment was performed transfecting the
cells with only Nucleofector Solution (Amaxa). Relative expres-
sion is reported in percent referred to the control. B) MMP-2
activity in young AoSMCs silenced for MMP-2 by zymography.
106 cells were transfected with 5 g of siRNA against MMP-2
(siMMP-2) or 5 g of scramble siRNA (scramble) or with only
Nucleofector Solution (control). 2 g of each conditioned cell
medium were loaded in the gel. C) Migration of young MMP-2-
silenced AoSMCs. 1  105 cells, transfected with 5 g of siRNA
against MMP-2 (siMMP-2) or 5g of scramble siRNA (scramble)
or with only Nucleofector Solution (control), were seeded in the
upper chamber of gelatin-coated Transwell apparatus. As con-
trol, 0.3 g/ml active-MMP-2 (Calbiochem) was added to the
lower chamber of the Transwell (siMMP-2MMP-2). After 6 h of
incubation at 37°C, migrated cells were stained with Crystal
violet and counted.
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molecular concentration such as cellular metabolism,
tissue compositions, DNA damage, and many others
(for a review, see ref 31). Even though the mechanism
of aging is far from being understood, it is well estab-
lished that cellular senescence occurs in vivo and in
vitro. Therefore, cellular senescence may be a useful
tool to study aging processes (29). As aging is a major
risk for cardiovascular disease, which represents the
most important cause of death in western countries, we
have developed a cellular system to study age-related
modifications in AoSMC, critical components of the
vascular wall. A large body of evidence supports the in
vitro aging model; for instance, the comparison of
telomere lengths between human endothelial cells
aged in vitro and those obtained from donors of
different ages do not show any difference (32).
As AoSMCs play a pivotal role in both physiological
and pathological processes that occur in vascular sys-
tem, we set up an in vitro aging model based on
sequential cell passages (population doublings) in
vitro. Moreover, the relationship between in vitro and
in vivo aging was described by Martin et al. (33), who
reported that replicative capabilities of human SMC
cultures decline with donor aging; in our cultures we
obtained a similar growth decrease during progressive
cell passages (results not shown). In fact, in our aged
AoSMC cultures we detected the senescent phenotype
visualizing both SA -Gal activity, which is proposed as
an effective marker of cell senescence as telomere
length (24, 28, 43), and cyclin-dependent inhibitor p16
mRNA, which was recently demonstrated to accumulate
in senescent cells (25). Moreover, to exclude AoSMC
dedifferentiation events, we have ruled out such phe-
nomena detecting the same expression and cellular
distribution of the typical AoSMC markers (i.e., -SMA
and calponin) in young as well as in aged cells. In our
model, we found other aspects typical of aged AoSMCs
such as increased cell size and trypsin digestion resis-
tance (35). Hence, the simultaneous expression of
senescent markers and SMC phenotypical proteins
indicates that controlled sequential passages in vitro
can be considered a valid model to study age-related
modifications in AoSMCs.
In this work, we describe a clear regulation of MMP-2
activity during the aging process, and how such regula-
tion affects the migration of AoSMCs. Only in condi-
tioned culture medium of young AoSMCs did we find
the active form of MMP-2. On the other hand, inactive
pro-MMP-2 was present at about the same amount in
young and aged cell conditioned medium by means of
gel zymography, ELISA quantification, and Western
blot analysis. This result is strictly related to the quan-
tification of MMP-2 mRNA performed with real-time
RT-PCR. In fact, no significant differences were de-
tected between the MMP-2 transcription concentration
in young and aged AoSMCs. The related gelatinase
MMP-9 was not detected in our cell model, in agree-
ment with a previous study reporting that, in mouse
SMC, MMP-9 expression is present only after injury or
inflammatory stimulation (11).
Figure 9. Knockdown of TIMP-2 in aged AoSMCs. A) Quan-
tification of the transcripts coding for TIMP-2 by real-time
RT-PCR in aged cells transfected with 5 g of siRNA against
TIMP-2 (siTIMP2) or 5 g of scramble siRNA (scramble)
after 48 h. The control experiment (control) was performed
transfecting the cells with only Nucleofector Solution
(Amaxa). Relative expression is reported in percent referred
to the control. B) Western blot analysis on 10 concentrated
conditioned medium of aged AoSMCs transfected with 5 g
of siRNA against TIMP-2 (siTIMP2) or 5 g of scramble
siRNA (scramble) after 48 h using anti-TIMP-2 antibodies. C)
Migration of aged TIMP-2-silenced AoSMCs. 1  105 cells,
transfected with 5 g of siRNA against TIMP-2 or 5 g of
scramble siRNA or with only Nucleofector Solution, were
seeded in the upper chamber of gelatin-coated Transwell
apparatus. As control, 0.3 g/ml purified TIMP-2 (Calbio-
chem) was added to the lower chamber of the Transwell
(siTIMP2TIMP2). After 6 h of incubation at 37°C, migrated
cells were stained with Crystal violet and counted.
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MMP activity is implicated in various vascular diseases
like hypertension, arterial restenosis, atherosclerosis,
and aortic aneurismal disease (36). Because there is a
direct correlation between aging and the development
of circulatory diseases, some studies raised the hypoth-
esis that aging could cause a MMPs activation, then
pathology onset (37). Other authors indicate in the
inflammatory process occurring in aged vascular tissue
the trigger that activates the MMPs (38). To avoid the
effect of inflammatory stimuli and to simplify the
model, AoSMCs are cultured in vitro without the com-
plex and not yet fully identified signals deriving from
the surroundings cells that are present in vivo. This
in vitro aging system could be considered a not patho-
logical aging model as lacking the signaling deriving
from other cells. From another point if view, our model
can more carefully identify the real role of AoSMCs in
aging process. Moreover, a recent paper reported that
an increase of MMP-2 activity can be detectable in
healthy human aorta specimens from donors of differ-
ent ages (37). Such an MMP-2 increase was detected
mainly in the aorta intima layer where AoSMCs are not
present, highlighting a peculiar spatio-temporal spe-
cialization of each cells types populating the vessel
walls. The data about MMPs activation were often
obtained from whole tissue specimens, and therefore
lacked the specific role of a single cell type in pathology
onset. However, comparing the gene expression of
MMPs and their regulators in fetal and aged (70 years
old) human aorta samples, we detected an evident
agreement between results obtained in our in vitro
model and in vivo specimens. This finding could dem-
onstrate that the MMP-2 regulation observed in vitro
could also be present in vivo during natural aging, even
if further investigation must be done to elucidate this
point at a functional concentration.
Activation of the pro-MMP-2 in MMP-2 is achieved by
several mechanisms involving other proteins (i.e., other
MMPs, thrombin, and plasmin) (39). MT1-MMP plays a
crucial role in pro-MMP-2 activation, and we have
found an increase of MT1-MMP mRNA and protein in
young AoSMCs in accordance with the elevated activa-
tion of pro-MMP-2 detected in such cells. Even if it were
contradictory, MT1-MMP pro-MMP-2 activation mech-
anism involves the specific MMP-2 inhibitor TIMP-2. In
fact, TIMP-2 is necessary as a docking element between
pro-MMP-2 and MT1-MMP, thus allowing the cleavage
of the propeptide of pro-MMP-2 by MT1-MMP (8, 40,
41). Based on this consideration, we have visualized a
higher TIMP-2 activity in total protein extracts pre-
pared from young than aged AoSMCs. Cell-associated
TIMP-2 represents the intracellular and MT1-MMP-
bound inhibitor. The intracellular TIMP-2, which is
associated with lysosomes and endosomes fractions, is
destined to a rapid degradation (42) whereas mem-
brane-associated TIMP-2 represents the major fraction
of cellular TIMP-2, as clearly shown by confocal immu-
nolocalization both on cultured cells and in vivo (43–
45). Therefore, although we could not directly demon-
strate the real MT1-MMP/TIMP-2/pro-MMP-2 complex
formation, MT1-MMP and TIMP2 could be expressed
more in membrane of young AoSMC than in that of aged
cells, indicating that pro-MMP-2 activation complex (i.e.,
MT1-MMP, TIMP2, and pro-MMP-2) may be more abun-
dant in young cells, leading therefore to more efficient
activation of pro-MMP-2.
As TIMPs play a critical role not only in the modula-
tion of MMP-2 activity, but also in the conversion from
inactive to active form of the enzyme, we have focused
our attention on TIMP expression in young and aged
AoSMCs by means of quantitative real-time RT-PCR,
reverse zymography, and Western blot analyses. We
found elevated TIMP-1 and TIMP-2 mRNA expression
and activity in aged AoSMCs, thus supporting the
hypothesis of an inhibition of MMP-2 activation in aged
cells, which could also depend on an up-regulation of
TIMP messengers. Although TIMP-1 and TIMP-2 have a
wide range of substrates and can also be active on
MMP-2, the specific inhibitor of MMP-2 is TIMP-2 (46).
TIMP-2 inhibitory activity was found to be higher in the
conditioned cell culture medium of aged than of young
AoSMCs, confirming the quantification of TIMP-2
mRNA performed by real-time RT-PCR. The fine regu-
lation of activators and inhibitors of MMP activities has
been demonstrated to play a pivotal role in the onset of
different pathologies of the vascular system (36) as well
as tumor growth and invasion (47), osteoarthritis (48),
and recently in plasma of women who subsequently
developed preeclampsia (49). Therefore, a large body
of evidence suggests that the unbalance between MMPs
and TIMPs is critical in the pathophysiology not only in
the vascular system, but also in other tissues.
In the postgenomic era, the scientific community is
trying to answer the question “how genes are regulated”
as the gene identification step has been reported (50,
51). However, from a physiological point of view it
would be important to study cell behavior in correla-
tion with cell gene expression. As the migration of
vascular SMCs plays an important role in the produc-
tion of the thickened intima after vascular injury (52)
and also in the neovascularization that occurs during
wound healing, ischemia, postinterventional restenosis
and the formation of advanced atherosclerotic plaques,
we investigated whether the different activity of MMP-2
in young and aged AoSMCs affects cell migration
properties. By means of modified Boyden chamber
assays using Transwell apparatus coated with gelatin, in
order to have a micro-environment resembling vascular
basal membrane (53), we measured higher migration
capabilities in young in comparison to aged cells
(Fig. 4). These data are in agreement with Ruiz-Torres
et al. (54), who describe that human SMCs from old
donor possess a lower migration rate than SMCs from
young donor. Nevertheless, contradictory results have
been obtained comparing the migratory behavior of
SMCs from young or aged rat aorta (19) indicating
that a probable species-specific differences in the
aging process could exist (54). In fact, aging may be
an atypical biological process, because no genes
appear to have evolved specifically to cause it (55).
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Indeed, because age-related changes are the unpro-
grammed results of stringent selection for early
reproductive process, aging may be an example of a
biological phenomenon where there is a low concen-
tration of mechanistic conservation between diverse
metazoans (56).
The decreased MMP-2 activity and increased TIMP-1
and TIMP-2 expression address the question of whether
MMP-2 affects cell migration in our system. Hence,
human purified TIMP-1 and TIMP-2 were added to
young AoSMCs to mimic the TIMP expression concen-
tration of aged cells. As proposed in our hypothesis,
young AoSMCs treated with TIMP-2 migrated as aged
cells, whereas TIMP-1-treated cells showed only a 25%
of migration inhibition. This result could be justified
considering the nonspecific effect of TIMP-1 on MMP-2
(15). We also treated aged AoSMCs with either TIMP-1,
TIMP-2, or human active purified MMP-2. TIMP treat-
ments did not further inhibit the migration of aged
AoSMCs. This could be explained considering that
MMP and TIMP complexes are in a 1:1 M ratio (15); an
extra addition of TIMP to cells that already expresses
such proteins could not produce any more MMP inhi-
bition. Human active purified MMP-2 was added to
aged AoSMCs to mimic young cell behavior and, as
expected, the migration of aged cells reached the
concentration observed in young cells.
When we inhibited the gelatinase activities of young
AoSMCs using GM6001, also known to inhibit a wide
range of proteases, including the ADAM family, we
found a slower migration similar to results obtained
with TIMP-2-treated cells. This indicates that MMP-2/
TIMP-2 were the major proteins involved in migration
control of AoSMC. However, this was an indirect evi-
dence, and we have specifically demonstrated the piv-
otal role of MMP-2 and TIMP-2 silencing MMP-2 by
siRNA in young cells and TIMP-2 in aged cells. Both
transfections reached a very high yield of inhibition
decreasing the presence of MMP-2 and TIMP-2 tran-
scripts of the 95% and 80%, respectively. Such a
difference in transfection efficiency could be explained
considering the difficulty of aged (high PD) cells to be
transfected efficiently. siRNA MMP-2-silenced young
AoSMCs showed decreased migratory properties that
could be recovered by adding human active purified
MMP-2. By contrast, TIMP-2-silenced aged AoSMCs
increased migratory properties that could be reverted
by adding human recombinant TIMP-2. In this way, we
were able to obtain in young cells the MMP-2 inhibition
typical of aged AoSMCs and in aged cells the typical
MMP-2 activation of young AoSMCs. These experi-
ments support the pivotal role of the ratio MMP-2:
TIMP-2 to control the migration of AoSMC during
in vitro aging. The lower MMP-2 activity, and then the
lower migration capability of aged cells reported in
in vivo studies, could be correlated with the minor
presence of SMC in atheromatous plaque from older
patient carotids (57). In such “aged plaque” decreased
MMP-2 activity, an increase of MMP-9 activity and CD68
positive cells clearly demonstrates that other cells (i.e.,
macrophages) could modify the behavior of resident
cells modulating the ECM composition through inflam-
matory process. The central role of MMP-2 in the
pathophysiology of vascular system was recently con-
firmed in MMP-2 knockout (KO) mice (6). In fact
AoSMCs from MMP-2 KO mice showed limited migra-
tory capabilities; moreover, the MMP-2 KO mice
showed a very limited intimal thickening during carotid
artery injury, indicating the critical role this enzyme
plays in the physiopathology of blood vessels in vivo.
In conclusion, we have reported an inhibition of
MMP-2 activity during sequential AoSMC culture pas-
sages that could originate from an increase of TIMP-1
and TIMP-2 or a decrease of MT1-MMP. We also
demonstrated that during in vitro aging the AoSMC
migration decreases and such cellular behavior can be
strictly regulated by MMP-2 and TIMP-2 activities.
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